{"id":9229,"date":"2021-06-29T10:43:41","date_gmt":"2021-06-29T10:43:41","guid":{"rendered":"https:\/\/www.kolabtree.com\/blog\/?p=9229"},"modified":"2021-11-12T10:07:55","modified_gmt":"2021-11-12T10:07:55","slug":"innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville","status":"publish","type":"post","link":"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/","title":{"rendered":"Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville"},"content":{"rendered":"<p><i><span style=\"font-weight: 400;\">This article is the first in a series of Innovators Speak, where <a href=\"https:\/\/www.kolabtree.com\/?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=InnovatorSpeakJG\">Kolabtree<\/a> chats with the world\u2019s leading scientific and business innovators such as Jacob Glanville, and picks their brains on the latest advancements in science and technology, how academics are switching to remote working within a rapidly burgeoning <a href=\"https:\/\/www.kolabtree.com\/blog\/gig-economy-trends-2021-the-birth-of-an-expert-economy\/?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=InnovatorSpeakJG\">expert economy<\/a>, how the pandemic is shaping our future and much more.<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400;\">In this interview, Jacob Glanville sits down with <a href=\"https:\/\/www.kolabtree.com\/?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=InnovatorSpeakJG\">Kolabtree<\/a> CEO Ashmita Das to discuss Centivax going into clinical trials on June 1 with their <b>SARS COV 2<\/b> antibody vaccine, and how maintaining a lean model has helped keep the costs down.\u00a0<\/span><\/p>\n<p><iframe loading=\"lazy\" title=\"Innovators Speak E01: Kolabtree CEO Ashmita Das interviews Centivax CEO Jacob Glanville\" width=\"702\" height=\"395\" src=\"https:\/\/www.youtube.com\/embed\/79U1jS7bV2Q?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Jacob Glanville is an immuno-engineer and entrepreneur, developing the core business model and technology for Distributed Bio and its spin-off\u00a0<\/span><a href=\"https:\/\/www.centivax.com\/?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=InnovatorSpeakJG\"><span style=\"font-weight: 400;\">Centivax.<\/span><\/a><span style=\"font-weight: 400;\"> Both companies follow a lean business model to minimise redundancy and maximise efficiency, resulting in sustained profits without external investment. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Here, Jacob Glanville (JG) sits down with Ashmita Das (AD), CEO of <\/span><a href=\"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/?utm_source=StoneJunction&amp;utm_medium=blogging&amp;utm_campaign=KOL301\"><span style=\"font-weight: 400;\">Kolabtree<\/span><\/a><span style=\"font-weight: 400;\">,\u00a0to discuss Centivax\u2019s experience of going into clinical trials\u00a0 with its\u00a0SARS COV 2\u00a0antibody vaccine, and how maintaining a lean model has helped keep costs down.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\"><strong>AD<\/strong>: Jacob, you have an incredible career history to date \u2014 <\/span><span style=\"font-weight: 400;\">you\u2019ve received grants and awards from the Gates Foundation, you are a National Institute of Health principal investigator and have been featured in a Netflix documentary. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">You were a guest lecturer at Stanford and USF and are also a principal scientist at Pfizer. In 2012, you co-founded Distributed Bio and you are now running its spin off Centivax, making you a serial entrepreneur and inventor, computational immuno-engineer, among other things. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">How would you describe yourself in your work?<\/span><\/p>\n<p><b>JG<\/b><span style=\"font-weight: 400;\">: I\u2019m an immune hacker, so I use mathematics, computers and good old-fashioned roll up your sleeves wet lab work to interrogate the immune system and figure out how to get the best responses out of it. This information can help us treat various diseases and harness therapeutic molecules directly out of the immune system, like monoclonal antibodies that can serve as drugs.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">T<\/span><span style=\"font-weight: 400;\">he immune system affects pretty much every disease \u2014 <\/span><span style=\"font-weight: 400;\">from <\/span><span style=\"font-weight: 400;\">the obvious things like infections <\/span><span style=\"font-weight: 400;\">to other conditions <\/span><span style=\"font-weight: 400;\">like cancer<\/span><span style=\"font-weight: 400;\">,<\/span><span style=\"font-weight: 400;\"> nerve degeneration and heart disease<\/span><span style=\"font-weight: 400;\">.<\/span> <span style=\"font-weight: 400;\">You\u2019re often <\/span><span style=\"font-weight: 400;\">hard<\/span><span style=\"font-weight: 400;\">&#8211;<\/span><span style=\"font-weight: 400;\">pressed to find somewhere in medicine where the immune system isn\u2019t involved because your immune system is designed to detect changes in tissues, and that\u2019s what disease is.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">And then on the flipside, it\u2019s also a great source of medicines like antibodies and allows us to develop our understanding of how to produce better broad-spectrum vaccines. All these cool applications have become much easier to attack with vigour with the emerging golden age of biotechnology. We have high-throughput genomic sequencing instruments, high-throughput DNA synthesis instruments, and a plethora of single-cell sequencing technologies and microfluidics. Therefore, part of my job is understanding that system and coming up with engineering tactics for creating medicines that can treat problems that have plagued us since the beginning of time.<\/span><\/p>\n<p><b>AD: Can you talk a little bit about your latest venture, Centivax? What\u2019s the vision for<\/b> <b>this new company?<\/b><\/p>\n<p><b>JG<\/b><span style=\"font-weight: 400;\">: This has been my long-range plan and dream and I\u2019ve finally been able to manifest it. Centivax was founded on the idea of being able to harness the technologies that I spent time optimising and engineering first as an advisor and then in my first venture Distributed Bio. Now I\u2019m finally ready, with a decade of <a href=\"https:\/\/www.kolabtree.com\/blog\/ensuring-reproducibility-in-ai-driven-research-how-freelance-experts-can-help-in-biotech-and-healthcare\/\">research<\/a>, to use these technologies to build antibodies or even provoke them out of a living organism that bind to the Achilles heels of viruses and pathogens. When you get the right antibody against that special site, they tend to be much more effective. In the case of the coronavirus, we are now getting ready to start our clinical studies on an antibody.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">With our broad-spectrum vaccine technology, we teach the immune system to make specific antibodies. For a snake bite, we could develop a vaccine from someone whose body had generated antibodies that were able to bind to sites across venom from all snakes \u2014 this is the kind of application I\u2019d like to tackle. There are also important applications in autoimmunity and oncology, where you are targeting mutating and diverse populations, and we could hack those systems well. That\u2019s the strength of our technology, our goal is creating substantial advances using new technologies to attack these systems.<\/span><\/p>\n<p><b>AD: So when you say you\u2019re immuno-hacking, what you\u2019re trying to do is take the natural responses our bodies produce and use that as the therapeutic.<\/b><\/p>\n<p><b>JG<\/b><span style=\"font-weight: 400;\">: We extend beyond what the human body can produce. The problem with the human body is that when pathogens, cancers and autoimmunity strike, they have hacked our immune system. There\u2019s this never-ending arms race of trying to have a diversity of the pathogen or the cancer against the diversity of our immune system. And these two armies have met at war since the beginning of time, and they both learned each other\u2019s weaknesses.\u00a0 And that\u2019s where the stalemate arises and you get sick.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">We engineer beyond what nature can deliver. We learn how to use these systems so we can hack beyond where nature naturally gets stuck. That\u2019s nature \u2014 it doesn\u2019t normally produce a broad, neutralising response against all influenza and, for instance, we don\u2019t currently have a working HIV vaccine.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That\u2019s where our technology comes in. We ask ourselves, where is the defect, and then we engineer to try to push beyond what nature has provided so that we can actually win some of these forever wars against pathogens. The golden age of biotechnology can help us push back past the stalemate and achieve victory. And I will say that sounds ambitious, but I\u2019ll remind you we were able to eradicate smallpox, and we have almost eradicated several other pathogens. There has been remarkable success in vaccine science and multiple Nobel Prizes awarded around monoclonal antibodies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">But those technologies are still operating based on last century\u2019s biotechnology capabilities, so we\u2019re bringing in new technologies to be able to make better engineered medicines to break through the continued limitations of nature.\u00a0<\/span><\/p>\n<p><b>AD: With Centivax you\u2019re currently creating an antibody therapeutic treatment for the coronavirus, and I understand it\u2019s going into clinical trials. What\u2019s the progress on this and what role do you see it playing?<\/b><\/p>\n<p><b>JG<\/b><span style=\"font-weight: 400;\">: I initiated this programme at the beginning of the outbreak and, because my team specialises in pandemic medicine, we knew right away there were going to be two big problems to address.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">We knew the virus was going to start mutating and so there were efforts to produce antibody therapies quickly. When they came out, many were already being revoked by the FDA because the new mutant versions of the virus, which are more infectious and may be more deadly, were causing those early antibodies to no longer bind effectively to the virus. We spent the time engineering an antibody that binds to an Achilles heel, a very sensitive part of the virus on all the new emerging strains.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Secondly, I could anticipate that it was going to be a major problem to try to deliver a normal antibody therapy in the midst of a pandemic, and the reason for that is that with normal antibody therapies you have to give a big dose in an infusion bag, and that means having a specialist treat you in an infusion centre.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The problem in a pandemic is that in any location where you could receive an IV, those areas are already full of very sick patients. The best time to give an antibody therapy is as early as possible \u2014 the problem is if you call immediately and request the antibody therapy, the doctors will likely say that you\u2019re not sick enough. But then you risk getting sicker, so by the time you arrive you\u2019re in a much worse position \u2014 this was a problem we wanted to address and that\u2019s where our engineering advantage comes in. We were able to engineer an antibody to produce ultra-high concentrations that\u00a0 fit into an injectable syringe. Therefore, patients don\u2019t need to go to an infusion centre, they just get a pop in the arm or in the leg and get the medicine early. We can deliver a smaller dose and we can give it much earlier, which means we can produce many more doses than beforehand.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This is a powerful way to transform how scary this pathogen is \u2014 you can get a shot early so you don\u2019t get sick in the first place. You don\u2019t risk going to the hospital. You don\u2019t risk death and we believe that it will avoid some of the long-collar risk of the complications that arise from a serious infection.<\/span><\/p>\n<p><b>AD: So if you don\u2019t mind just digging a little deeper. You know giants like Pfizer,<\/b> <b>they obviously do have a critical role to play in very many areas, including funding, mass producing drugs and driving large scale clinical trials.\u00a0<\/b><\/p>\n<p><b>But I also firmly believe that a lot of innovation happens on the ground among smaller biotech or other types of organisations. These are probably organisations with less than 100 people. Would you agree? Do you think that a lot of the innovation is driven by smaller players?<\/b><\/p>\n<p><b>JG<\/b><span style=\"font-weight: 400;\">: The answer is yes, and here\u2019s why. I spent four years working at Pfizer, which was a juggernaut. I then spun out to create my first and now second company. In Distributed Bio, my first company, I ended up running 78 antibody discovery and optimisation programmes for about 60 different pharmaceutical and small biotech companies. Through that process, I ended up meeting hundreds of companies, many of which became my clients and these ranged from major pharmas to small biotechs, and that gave me an opportunity to watch the trends in the industry and see how they were shifting.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The big change is that traditionally everything occurred within the hallowed halls of a major pharmaceutical company. You had a department for hybridoma, a department for manufacturing, a department for safety etc.\u00a0 Modern pharma has split that out into a constellation of contract research organisations (CROs), which has enabled many of my previous clients and now my own company to run clinical trials and to partner with. For example, we partnered with Charles River Laboratories for safety and talks, and with another regulatory specialist to do our clinical study with the military.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">There are groups you can reach out to, and big pharma companies have realised this and started downsizing. They keep themselves strategically lean. They have a key set of experts that are difficult to outsource because that\u2019s central to their core mission, but, otherwise, they reach out to either consultants or to contract groups when they can.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Of course you want to establish good relationships with CROs or consultants. However, you may want them, for a period of, say, four months, and then you don\u2019t need them again. But if you like them, you call them up again six months from now, and it\u2019s that periodic access and the use of an existing expert outside without having to build everything internal that allows companies like mine to remain relatively lean.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">To watch the full interview with Jacob Glanville, visit <\/span><a href=\"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/?utm_source=StoneJunction&amp;utm_medium=blogging&amp;utm_campaign=KOL301\"><span style=\"font-weight: 400;\">https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/<\/span><\/a><span style=\"font-weight: 400;\">.\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Watch Jacob Glanville talk about specific issues such as vaccinations and the growing significance of biotech here &#8211;\u00a0 https:\/\/www.youtube.com\/channel\/UCLAvq8HIDTKahLWzYoY2rgg\/videos<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This article is the first in a series of Innovators Speak, where Kolabtree chats with the world\u2019s leading scientific and business innovators such as Jacob Glanville, and picks their brains on the latest advancements in science and technology, how academics are switching to remote working within a rapidly burgeoning expert economy, how the pandemic is<\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/\" title=\"Read More\">Read More<\/a><\/div>\n","protected":false},"author":605,"featured_media":9242,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[442,317,305,558,403,443,205,540],"tags":[489,531,84,553],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.1 (Yoast SEO v20.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville -<\/title>\n<meta name=\"description\" content=\"Centivax CEO Jacob Glanville talks about manufacturing Covid-19 vaccines, the rise of remote working and the importance of freelance scientists.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville\" \/>\n<meta property=\"og:description\" content=\"Centivax CEO Jacob Glanville talks about manufacturing Covid-19 vaccines, the rise of remote working and the importance of freelance scientists.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/\" \/>\n<meta property=\"og:site_name\" content=\"The Kolabtree Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kolabtree\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-29T10:43:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-12T10:07:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kolabtree.com\/blog\/wp-content\/uploads\/2021\/06\/Innovators-Speak-Jacob-Glanville.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Naren Madan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@kolabtree\" \/>\n<meta name=\"twitter:site\" content=\"@kolabtree\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Naren Madan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville -","description":"Centivax CEO Jacob Glanville talks about manufacturing Covid-19 vaccines, the rise of remote working and the importance of freelance scientists.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/","og_locale":"en_US","og_type":"article","og_title":"Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville","og_description":"Centivax CEO Jacob Glanville talks about manufacturing Covid-19 vaccines, the rise of remote working and the importance of freelance scientists.","og_url":"https:\/\/www.kolabtree.com\/blog\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/","og_site_name":"The Kolabtree Blog","article_publisher":"https:\/\/www.facebook.com\/kolabtree","article_published_time":"2021-06-29T10:43:41+00:00","article_modified_time":"2021-11-12T10:07:55+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.kolabtree.com\/blog\/wp-content\/uploads\/2021\/06\/Innovators-Speak-Jacob-Glanville.png","type":"image\/png"}],"author":"Naren Madan","twitter_card":"summary_large_image","twitter_creator":"@kolabtree","twitter_site":"@kolabtree","twitter_misc":{"Written by":"Naren Madan","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/#article","isPartOf":{"@id":"https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/"},"author":{"name":"Naren Madan","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/491011190655ca387dd093278b938927"},"headline":"Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville","datePublished":"2021-06-29T10:43:41+00:00","dateModified":"2021-11-12T10:07:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/"},"wordCount":1949,"commentCount":0,"publisher":{"@id":"https:\/\/www.kolabtree.com\/blog\/#organization"},"keywords":["biotech startups","Coronavirus","Entrepreneur","pandemic"],"articleSection":["Biotechnology","Business support","Collaboration","COVID-19 resources","Future of work","Healthcare","Kolabtree News","Medical Devices"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/","url":"https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/","name":"Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville -","isPartOf":{"@id":"https:\/\/www.kolabtree.com\/blog\/#website"},"datePublished":"2021-06-29T10:43:41+00:00","dateModified":"2021-11-12T10:07:55+00:00","description":"Centivax CEO Jacob Glanville talks about manufacturing Covid-19 vaccines, the rise of remote working and the importance of freelance scientists.","breadcrumb":{"@id":"https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kolabtree.com\/blog\/de\/innovator-speak-kolabtree-interviews-centivax-ceo-jacob-glanville\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kolabtree.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Innovators Speak: Kolabtree Interviews Centivax CEO Jacob Glanville"}]},{"@type":"WebSite","@id":"https:\/\/www.kolabtree.com\/blog\/#website","url":"https:\/\/www.kolabtree.com\/blog\/","name":"The Kolabtree Blog","description":"Expert Views on Science, Innovation and Product Development","publisher":{"@id":"https:\/\/www.kolabtree.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kolabtree.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kolabtree.com\/blog\/#organization","name":"Kolabtree","url":"https:\/\/www.kolabtree.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Kolabtree"},"image":{"@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kolabtree","https:\/\/twitter.com\/kolabtree","https:\/\/instagram.com\/kolabtree","https:\/\/www.linkedin.com\/company\/kolabtree","https:\/\/en.m.wikipedia.org\/wiki\/Kolabtree"]},{"@type":"Person","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/491011190655ca387dd093278b938927","name":"Naren Madan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/cf6290c8bf4ceb18ef54b6e9000cd287?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cf6290c8bf4ceb18ef54b6e9000cd287?s=96&d=mm&r=g","caption":"Naren Madan"},"url":"https:\/\/www.kolabtree.com\/blog\/author\/naren-madan\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/9229"}],"collection":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/users\/605"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/comments?post=9229"}],"version-history":[{"count":11,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/9229\/revisions"}],"predecessor-version":[{"id":9705,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/9229\/revisions\/9705"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/media\/9242"}],"wp:attachment":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/media?parent=9229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/categories?post=9229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/tags?post=9229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}